ProSpare reduces anorectal dose during postoperative prostate radiotherapy in the randomized POPS trial

ProSpare reduced anorectal dose and showed lower grade ≥1 bowel toxicity at 18 weeks, while the trial's primary two-year endpoint remains pending.

KEY POINTS

  • The POPS trial (NCT02978014) is a randomized, multicenter phase II study conducted across 10 UK centers, evaluating the self-inserted ProSpare rectal obturator during postoperative prostate bed radiotherapy. Between 2017 and 2023, 162 patients were randomized, and 158 received treatment, including 77 assigned to ProSpare and 81 to standard care.
  • ProSpare incorporates radiopaque markers to support daily CBCT-based localization and permits a reduced 5-mm posterior PTV margin, compared with a median 10-mm posterior margin in the standard-care arm. Protocol-recommended prostate bed schedules included 66 Gy in 33 fractions or 55 Gy in 20 fractions; 53% received moderately hypofractionated RT, and 17% underwent pelvic nodal irradiation.
  • At 18 weeks, clinician-reported RTOG grade ≥1 gastrointestinal toxicity was 31.4% with ProSpare versus 39.4% with standard care, while grade ≥1 genitourinary toxicity was 28.6% versus 36.8%. These differences favored ProSpare numerically, but the prespecified early analysis was descriptive and did not establish statistical superiority.
  • Grade 2 toxicity remained uncommon and similar between groups. At 18 weeks, RTOG grade 2 GI toxicity occurred in 4.3% versus 4.0%, and grade 2 GU toxicity in 4.3% versus 2.6%, for ProSpare and standard care, respectively. No RTOG grade ≥3 events were observed at that assessment, although one CTCAE grade 3 urinary incontinence event occurred in the ProSpare arm.
  • Dosimetric analysis in 122 patients (61 per arm) demonstrated consistently lower anorectal dose-volume exposure with ProSpare. Median relative reductions across the assessed dose-volume parameters ranged from 2.7% to 44.6% for the rectum and 39.8% to 54.5% for the anal canal, with the largest differences generally occurring at higher dose levels.
  • Device tolerability was favorable: 50 of 51 respondents (98%) considered ProSpare tolerable, 49 of 51 (96.1%) would recommend it to reduce side effects, and 98.5% reported no or only minor discomfort. After familiarization, 82.8% described insertion as very or quite easy, and no serious device-related adverse events were reported.
  • Patient-reported bowel, urinary, sexual, and general quality-of-life scores showed no meaningful between-arm differences at 18 weeks. The trial's primary endpoint is patient-reported EPIC bowel function and bother at two years, which has not yet been reported; therefore, the observed dosimetric improvements cannot currently be assumed to produce clinically meaningful long-term toxicity reductions.

CLINICAL TAKEAWAY

ProSpare provides a practical approach to improving anorectal dosimetry and supporting smaller posterior margins during postoperative prostate bed radiotherapy, with excellent patient-reported tolerability. However, the early toxicity differences are descriptive, grade 2 events were similarly uncommon in both groups, and the awaited two-year patient-reported outcomes will determine whether these dosimetric advantages translate into meaningful clinical benefit.

SOURCE

Frontiers in Oncology

Browse more research Suggest a correction